Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vertex

This Could Be the Next Blockbuster Drug Stock to Buy

Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.

Barchart

Vertex 2024 speaker: learn new art skills from creature designer Brynn Metheney

The Ghostbusters concept artist will be at Vertex 2024.

Creative Bloq

Why Investors Are Flocking to These 2 Medical Stocks

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review

The stock market rally hit fresh highs, with the S&P 500 hit 5,000. Arm and Palantir skyrocketed, with several other AI plays running higher.

Investors Business Daily

Vertex Is Trying To Replace Its Biggest Drug — Does It Stand A Chance?

Vertex could bolster its cystic fibrosis franchise with a next-generation drug, analysts said Tuesday. But VRTX stock dipped.

Investors Business Daily

Vertex Rebounds — But Its Alternative To Opioids Is 'Not A Game-Changer,' Says Analyst

Vertex's alternative to opioids is "not a game-changer," an analyst said Tuesday. But VRTX stock rebounded on the company's test results.

Investors Business Daily

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Vertex, IBD Stock Of The Day, Called 'Underappreciated Winner' For 2024

Vertex is the IBD Stock Of The Day as the maker of corporate tax compliance software expands its footprint with an acquisition.

Investors Business Daily

What incentives do scientists have to study rare diseases? | Explained

Explore the cutting-edge research of three Breakthrough Prize laureates in Life Sciences, and the systemic issues that influence access to treatments for three diseases desperately looking for cures: Parkinson’s disease, cystic fibrosis, and cancer.

The Hindu

Promising new gene therapies for sickle cell are out of reach in countries where they're needed most

New gene therapies promise a cure for sickle cell disease but experts say they are out of reach in places that need them the most

The Independent UK

Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment

Vertex solidified its potential for an alternative to opioids in pain treatment, an analyst said Wednesday. VRTX stock broke out.

Investors Business Daily

Vertex Stock Breaks Out On Phase 2 Results For Opioid Alternative

Vertex stock rallied 13% Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug.

Investors Business Daily

The Guardian view on cystic fibrosis treatments: a rollercoaster ride for the sick

Editorial: Patients are facing shorter lives as drug companies are demanding prices that health services here and in other countries cannot pay

The Guardian - UK

Vertex 2024 tickets now on sale!

VFX, game art, animation and more – grab your tickets to 2024's ultimate new event for the CG art community.

Creative Bloq

Get all your
news in one place.

100’s of premium titles.
One news app.

LiveScience

The world's 1st CRISPR therapy has just been approved. Here's everything you need to know

U.K. regulators have approved the use of a CRISPR therapy called Casgevy to treat two inherited blood disorders. But what is it and how does it work?

Creative Bloq

Vertex, the ultimate event for 2D and 3D artists, returns in 2024

The Vertex festival of digital art, VFX and animation is back in 2024.

Investors Business Daily

Crispr Surges After Winning The First-Ever Approval For A CRISPR-Based Gene-Editing Drug

In a world first, regulators in the UK approved Crispr's gene-editing treatment for two blood diseases on Thursday, and CRSP stock surged.

Homes & Gardens

Shark Stratos vs Vertex – which clinches best vacuum cleaner?

The decision between Shark Stratos vs Vertex can seem tricky. Shark vacuums are some of the best on the market. Here's what our expert tests revealed.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

‘Life-changing’ cystic fibrosis drugs approved for use in younger children

Campaigners welcomed the announcement by the Medicines and Healthcare Products Regulatory Agency.

Investors Business Daily

Dow Jones Futures Rise: What To Do As Market Pulls Back; Nvidia, Tesla At Key Levels

The S&P 500 win streak is over, on higher Treasury yields and Fed chief Powell comments. Nvidia, Tesla fell from key levels.

Investors Business Daily

Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus

VRTX stock investors are closely watching Vertex's efforts in pain treatment, analysts said Tuesday following mixed third-quarter sales.

Investors Business Daily

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug

The FDA appears likely to approve Crispr's gene-editing approach to sickle cell disease, analysts said Wednesday as CRSP stock gapped higher.

Investors Business Daily

Dow Jones Futures Rise: Jobs Report Due; Tesla Cuts Model 3, Y Prices Again

The jobs report is key for a struggling market rally attempt. Tesla cut Model 3 and Model Y prices again.

Investors Business Daily

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

Investors Business Daily

Meta Stock Leads 5 Names Showing Resilience In Market Downturn

Meta leads five resilient stocks worth watching. But investors need to be patient amid the market correction.

1 2 3 4 5

People

Jerome Powell

2,807 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations